Evidence map›Paper›PMID 23264826›Full record

ArticleDeutsches Arzteblatt international2012

The incidence of interval cancers in the German mammography screening program: results from the population-based cancer registry in North Rhine-Westphalia.

Oliver Heidinger, Wolf Ulrich Batzler, Volker Krieg, Stefanie Weigel, Cornelis Biesheuvel, Walter Heindel, Hans-Werner Hense

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in Deutsches Arzteblatt international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 51 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Mammography Screening - as of 2013.Geburtshilfe und Frauenheilkunde · 2013
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Oliver HeidingerEpidemiological Cancer Registry North Rhine-Westphalia, Münster, Germany. Oliver.Heidinger@krebsregister.nrw.de
Wolf Ulrich Batzler
Volker Krieg
Stefanie Weigel
Cornelis Biesheuvel
Walter Heindel
Hans-Werner Hense
Krebsgesellschaft Nordrhein-Westfalen · DEUniversity Hospital Münster · DEKrebsregister Saarland · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer screening programs must meet high standards for quality and effectiveness, because many healthy persons need to be screened to detect relatively few cases of cancer. In this study, we use the rate of interval cancers as an important surrogate indicator for evaluating the German mammography screening program (MSP).

methodsAll first-time participants in the MSP in the German federal state of North Rhine-Westphalia over the period 2005-2008 whose screening mammogram had been read as negative were followed over the next 24 months for the potential development of breast cancer (an "interval cancer" or IC). The screening data in the MSP database were compared in anonymized fashion with reports of cancer that were recorded at the Epidemiological Cancer Registry North Rhine-Westphalia.

resultsAmong the 878,764 women with negative screening mammograms in the first screening round, 2036 (23.2 per 10,000) developed an IC in the ensuing 24 months. These ICs accounted for 40% of all T2-T4 breast cancers occurring in first-time participants in the screening program in the 2 years after screening. The relative rate of IC compared to the background incidence of breast cancer before introduction of the MSP was 27% in the first year and 58% in the second. Screening detected 78% of all breast cancers that occurred during a maximum of 2 years after screening.

conclusionThe IC rates in the implementation phase of the MSP agree with those found in other, established European programs. The present study is the first one to assess this important surrogate parameter to characterize the effectiveness of the German MSP among women in North Rhine-Westphalia, Germany's largest state by population.

Indexed as

RegistriesAgedBreast NeoplasmsEarly Detection of CancerFemaleGermanyHumansIncidenceMammographyMass ScreeningMiddle AgedReproducibility of ResultsRisk FactorsSensitivity and Specificity

Identifiers

PMID23264826
PMCPMC3514772
OpenAlexW2128410971

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.